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Over the past decade there have been major advances in deﬁning the genetic basis of the majority of congenital myopathy subtypes.
However the relationship between each congenital myopathy, deﬁned on histological grounds, and the genetic cause is complex. Many of
the congenital myopathies are due to mutations in more than one gene, and mutations in the same gene can cause diﬀerent muscle
pathologies. The International Standard of Care Committee for Congenital Myopathies performed a literature review and consulted
a group of experts in the ﬁeld to develop a summary of (1) the key features common to all forms of congenital myopathy and (2) the
speciﬁc features that help to discriminate between the diﬀerent genetic subtypes. The consensus statement was reﬁned by two rounds
of on-line survey, and a three-day workshop. This consensus statement provides guidelines to the physician assessing the infant or
child with hypotonia and weakness. We summarise the clinical features that are most suggestive of a congenital myopathy, the major
diﬀerential diagnoses and the features on clinical examination, investigations, muscle pathology and muscle imaging that are
suggestive of a speciﬁc genetic diagnosis to assist in prioritisation of genetic testing of known genes. As next generation sequencing
becomes increasingly used as a diagnostic tool in clinical practise, these guidelines will assist in determining which sequence
variations are likely to be pathogenic.
 2013 The Authors. Published by Elsevier B.V.
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The congenital myopathies are a group of genetic
muscle disorders characterised clinically by hypotonia
and weakness, usually from birth, and a static or slowly
progressive clinical course. Historically the congenital
myopathies have been classiﬁed on the basis of the major
morphological features seen on muscle biopsy – e.g., rods
(nemaline myopathy), cores (central core disease and
multiminicore disease), central nuclei (centronuclear/
myotubular myopathy) and selective hypotrophy of type
1 ﬁbres (congenital ﬁbre type disproportion). Over the
past 15 years, the genetic basis of many of the diﬀerent
forms of congenital myopathy has been identiﬁed –
although it is evident that there are still many additional
genes to be discovered. The relationship between each
congenital myopathy, deﬁned on histological grounds,
and the genetic cause is complex for a number of reasons:
(1) Many of the congenital myopathies can be caused by
mutations in more than one gene (genetic
heterogeneity). For example, there are currently
eight known genetic loci for nemaline myopathy.
(2) Mutations in the same gene can cause diﬀerent
muscle pathologies. For example, mutations in
a-skeletal actin can result in nemaline myopathy [1,2],
intranuclear rod myopathy [3], actin accumulations
[4], congenital ﬁbre type disproportion (CFTD) [5],
cap disease [6], and zebra body myopathy [7].
(3) There are examples of the same genetic mutation
leading to diﬀerent pathological features in
members of the same family or in the same
individual at diﬀerent ages. Notably, this has been
demonstrated for mutations in the ryanodine
receptor gene (RYR1) and has been reproduced in a
mouse model of a RYR1 mutation [8].
In this overview, we will provide an approach to the
diagnosis of congenital myopathies and a guide to
identifying the genetic basis for an individual patient
based on clinical clues, muscle imaging (MRI) and
histological features on muscle biopsy. It is acknowledged
that the increasing use of exome, targeted sub-exomic
and whole genome sequencing as a diagnostic tool in
clinical practise is likely to reduce the need for muscle
biopsy as a ﬁrst line investigation. However a systematic
approach to clinical diagnosis will remain essential in the
initial assessment of patients and their families, and in
the interpretation of sequencing results to determine
which changes are likely to be pathogenic.2. Approach to developing this consensus statement
We initially performed a literature review and consulted
a group of experts in the ﬁeld of congenital myopathies to
describe:(1) the key clinical features common to all forms of
congenital myopathy that help to diﬀerentiate them
from other causes of muscle hypotonia and
weakness and
(2) the speciﬁc clinical features, muscle MRI ﬁndings and
pathological changes that help to discriminate between
the diﬀerent genetic subtypes for each of the congenital
myopathies that may assist in prioritizing diagnostic
testing (a “syndromic approach” to diagnosis).
We divided the phenotypic descriptions into two
age-groups to reﬂect the diﬀerent combinations of signs
the clinician is likely to be confronted with at the initial
evaluation of an infant or an older patient.
To complement the “expert” opinion, we developed a
questionnaire that was circulated to a wider group of
clinicians who care for patients with neuromuscular
disorders. The questionnaire focused on the features
that clinicians consider speciﬁc to congenital myopathies
(or were useful to exclude potential diﬀerential
diagnoses), as well as the phenotypic features that
distinguished the diﬀerent subtypes. In addition, we
surveyed current clinical practise and access to speciﬁc
investigations e.g., electron microscopy, muscle MRI,
genetic testing.
This ﬁnal “consensus” document combines the
information obtained by both approaches and will focus
on the following major forms of congenital myopathy:
 Nemaline myopathy (including cap disease and zebra
body myopathy and core-rod myopathy since these
appear to be pathological variants of nemaline
myopathy).
 Core myopathies (including central core disease and
multi-minicore disease).
 Centronuclear myopathies.
 Myosin storage myopathy (also known as hyaline
body myopathy).
 Congenital ﬁbre type disproportion.
We have speciﬁcally excluded three disorders that have
historically been grouped with the congenital myopathies
but which we no longer consider appropriate to be
classiﬁed in this way.
(1) Sporadic adult onset nemaline myopathy has a late
onset and rapidly progressive course. It is unclear
whether this entity has a genetic basis and some
cases are associated with a monoclonal gammopathy.
(2) Spheroid body myopathy and sarcotubular
myopathy due to mutations in TRIM32 and
myotilin (MYOT) should be classiﬁed with the
limb girdle muscular dystrophies and myoﬁbrillar
myopathies respectively.
(3) Reducing body myopathy due to mutations in FHL1
has a rapidly progressive, severe course that is
atypical of a true congenital myopathy.
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approach to diagnosis of the congenital myopathies in two
ways:
(1) A “phenotype down” approach that provides
guidelines to the physician assessing the infant or
child with hypotonia and weakness. We summarise
the clinical features that are most suggestive of a
congenital myopathy and discuss the major
diﬀerential diagnoses. Then we summarise the
features that are suggestive of a speciﬁc form of
congenital myopathy or a speciﬁc genetic diagnosis to
assist in prioritisation or interpretation of genetic
testing (Tables 1–4).
(2) A “genotype up” approach that provides a summary
of the features that are most suggestive of a speciﬁc
genetic diagnosis (Table 5).3. Deﬁning features of the congenital myopathies and
considerations in the diﬀerential diagnosis
There can be signiﬁcant clinical overlap between
congenital myopathies and other neuromuscular disorders
including the congenital muscular dystrophies (CMD),
congenital myotonic dystrophy, congenital myasthenic
syndromes (CMS), metabolic myopathies including
Pompe disease, spinal muscular atrophy (SMA), as well
as Prader–Willi syndrome, which can all present in the
newborn period with marked weakness and/or hypotonia
(‘ﬂoppy infant’).
Whilst it may not be possible to distinguish a congenital
myopathy from other disorders that present with
hypotonia, hyporeﬂexia and weakness – certain patterns
of clinical ﬁndings are suggestive; the presence of
prominent facial weakness with or without ptosis,
generalised hypotonic (‘frog-leg’) posture with
hyporeﬂexia, and weakness and dysfunction of the
respiratory and bulbar muscles. The extraocular muscles
may be involved in some forms, at presentation or
develop later in the course of the disorder. Sensation is
intact and intelligence is usually normal.
The severity of weakness and disability varies widely,
from neonates with profound generalised weakness to
patients with subtle weakness that ﬁrst manifests during
childhood with delayed motor milestones, or even later in
life with symptoms of proximal weakness. There is
usually reduced muscle bulk. Weakness is often
generalised or more prominent in limb-girdle and
proximal limb muscles although some congenital
myopathies have prominent axial and/or respiratory
muscle weakness or weakness of ankle dorsiﬂexion. In
patients with severe weakness, respiratory insuﬃciency is
common and the most severely aﬀected infants require
continuous ventilation for survival. In some congenital
myopathies, selective respiratory muscle involvement cancause nocturnal hypoventilation even though patients are
fully ambulant [9,10].
Several clinical features are uncommon in congenital
myopathies and if present, should alert the clinician to the
presence of an alternative diagnosis. These include
increased reﬂexes or central nervous system abnormalities
– although neonates with congenital myopathies have an
increased risk of perinatal asphyxia and may have co-
morbid hypoxic encephalopathy. The presence of tongue
fasciculations is suggestive of denervation, most commonly
due to SMA, and the presence of dysmorphism (other than
the “myopathic facies”) or metabolic abnormalities (such
as a raised lactate or metabolic acidosis) should prompt
the clinician to consider other diagnoses. A rapid
deterioration during the ﬁrst year is uncommon. Extreme
joint laxity is more often a sign of a collagen VI disorder
such as Ullrich CMD or a connective tissue disorder,
although it can be a prominent clinical feature of
congenital myopathies due to RYR1 [11].
Investigations other than muscle biopsy are rarely speciﬁc
for congenital myopathies, but are widely used to exclude
other possible diagnoses. Serum creatine kinase is usually
normal or mildly elevated and if raised more than ﬁve
times normal should prompt consideration of a muscular
dystrophy. It must be noted that serum creatine kinase is
often non-speciﬁcally elevated during the ﬁrst week of life.
Electromyography (EMG) and nerve conduction studies
(NCS) are most useful to exclude denervation disorders. In
congenital myopathies, the EMG is typically normal or
shows myopathic features, but occasionally changes that
appear neurogenic can be seen with severe neonatal
weakness or in distal muscles later in the disease course
[12]. Nerve conduction studies are normal. Speciﬁc
investigations such as repetitive nerve stimulation or single
ﬁbre EMG are important to exclude congenital myasthenic
syndromes, although some congenital myopathies can be
associated with neuromuscular junction abnormalities [13].
Over recent years muscle ultrasound and magnetic
resonance imaging (MRI) have been increasingly used to
diﬀerentiate between diﬀerent forms of congenital
myopathy. Selective muscle involvement on MRI can be
suggestive of a speciﬁc disease gene – however the
speciﬁcity is variable and imaging is usually interpreted in
conjunction with clinical phenotype and results of muscle
biopsy to prioritise gene testing. In the future – once data
has been collected to determine the speciﬁcity of patterns
of muscle involvement – muscle MRI may be used in
conjunction with clinical features to guide genetic testing
prior to muscle biopsy. Muscle ultrasound is a practical
way to image muscle that does not require general
anaesthetic and can be performed at the bedside.
However its utility is dependent on the expertise and
experience of the ultrasonographer. Muscle ultrasound
can also be helpful in recognising possibly neurogenic
changes and in selecting an appropriate muscle for biopsy.
Muscle biopsy and analysis of muscle histology,
histochemistry, immunohistochemistry and ultrastructure by
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reaching the diagnosis of a speciﬁc form of congenital
myopathy [14]. Historically the presence of dystrophic
features excluded a diagnosis of a congenital myopathy, but
mutations in MTM1, DNM2 [15], RYR1 [16] and ACTA1
[17] that are associated with severe early-onset disease can
cause prominent endomysial ﬁbrosis, variation in ﬁbre size
and fat inﬁltration, and can thus mimic a dystrophic pattern;
however ﬁbre necrosis is rare and usually absent. Mutations
in SEPN can result in multiminicore disease and congenital
ﬁbre type disproportion, in addition to congenital
muscular dystrophy with rigid spine [9].
4. Clinical clues to the diagnosis of speciﬁc forms of
congenital myopathy at diﬀerent ages
4.1. The neonatal and infantile period
One of the most distinctive and immediately
recognisable features of an infant with a congenital
myopathy can be very pronounced facial weakness, in
particular of the lower face and mouth (Table 1). The
mouth is held in an open position, typically with a tented
upper lip and the weakness present in the lower face is
usually out of proportion to any ptosis that may also be
present (see Fig. 1A). Facial weakness may be associated
with characteristic craniofacial dysmorphism consisting
of a long face, dolichocephalic skull and high arched
palate. Pronounced facial weakness ± dysmorphism isTable 1
Clinical clues particularly suggestive of speciﬁc diagnosis in congenital myopath
NM, nemaline myopathy; DM1, myotonic dystrophy type 1; CMS, congen
chondrial myopathy; MmD, multi-minicore disease; CCD, central core diseas
Pompe disease; COL6, Ullrich congenital muscular dystrophy.
(Please note that the table is meant to indicate if a clinical ﬁnding is a particu
occur in the other forms of congenital myopathy at lower frequency).particularly common in MTM1-related centronuclear
myopathy (also known as myotubular myopathy) and in
severe congenital-onset nemaline myopathy, severe
neonatal DNM2-related [15] and severe RYR1-related
myopathies, in particular those associated with recessive
inheritance [16,18]. The most important diﬀerential
diagnostic considerations are is congenital myotonic
dystrophy (DM1), and severe congenital myasthenic
syndrome (CMS). Moebius syndrome can also cause
severe facial weakness in the absence of more generalised
muscle weakness.
Ophthalmoparesis, often associated with ptosis, is an
important and diagnostically useful ﬁnding that should
be sought on clinical examination. Ophthalmoparesis is a
consistent feature in MTM1-related myotubular
myopathy and can also be seen in severe DNM2-related
CNM and in recessive RYR1-related myopathies
[15,16,19] (Fig. 1B). The ophthalmoparesis in all of these
myopathies may not be present in the neonate, but can
develop over the ensuing weeks to months or even years.
Ophthalmoplegia and ptosis can occur in CMS, and may
ﬂuctuate in severity. Mitochondrial cytopathies can also
cause ophthalmoparesis, but they rarely do so in the
newborn. Cataracts have been described in one case with
early-onset DNM2-related CNM [20].
Signiﬁcant bulbar weakness leading to insuﬃcient
sucking and swallowing is prominent in nemaline
myopathy, MTM1-related myotubular myopathy and the
centronuclear myopathies associated with severe DNM2ies: newborn and infant <2 years.
ital myasthenic syndromes; CNM, centronuclear myopathy; mito, mito-
e; PWS, Prader Willi syndrome; SMA, spinal muscular atrophy; Pompe,
lar clue to one of the congenital myopathies. Speciﬁc clinical ﬁndings can
Table 2
Clinical clues suggestive of speciﬁc diagnosis in congenital myopathies: older child.
Clinical feature Congenital myopathies Diﬀerenal diagnoses 
Scoliosis SEPN1, RYR1, NM COL6, LAMA2
Rigid spine SEPN1, RYR1
Cardiomyopathy TTN, MYH7, rarely ACTA1 Pompe disease
Foot drop/pes cavus  NM (NEB, TPM3, TPM2), DNM2, MYH7 Peripheral neuropathy
Malignant hyperthermia CCD, MmD and CNM (RYR1 only) 
Respiratory involvement and axial 
involvement out of proporon to 
skeletal muscle weakness  
SEPN1, NM (NEB, TPM3, ACTA1) LMNA, CMS, Pompe 
disease
NM, nemaline myopathy; COL6, collagen VI associated myopathy; CCD, central core disease; CMS, congenital myasthenic syndrome. (Please note that the table is
meant to indicate if a clinical ﬁnding is a particular clue to one of the congenital myopathies. Each clinical ﬁnding may occur in the other forms at lower frequency).
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diﬀerential diagnoses are Prader–Willi syndrome, CMS,
DM1 and severe SMA (type 0).
Signiﬁcant respiratory muscle involvement leading to
respiratory insuﬃciency at birth can occur in particular
in severe nemaline myopathy, MTM1-related myotubular
myopathy and occasionally in RYR1- and DNM2-related
myopathies [15,16,19,21]. Diﬀerential diagnoses include
DM1, CMS, SMA type 0, and Pompe disease. Spinal
muscular atrophy with respiratory distress type 1
(SMARD1) does not typically present with respiratory
failure at birth.
Very severe neonatal hypotonia without any antigravity
movements is suggestive of nemaline myopathy (most
likely ACTA1-, NEB- or KLHL40-related), MTM1-related
myotubular myopathy and severe forms of RYR1-related
myopathies, but is occasionally seen in severe DM1.
Orthopaedic complications are common. Early ﬁxed
kyphoscoliosis can occur in nemaline myopathy and
RYR1-related myopathies but is also seen in collagen VI-
related CMD (typically Ullrich), in severe CMS and in
Ehlers Danlos type VI (kyphoscoliotic type). Hip
dislocation at birth is particularly suggestive of RYR1-
related central core disease but is also frequently seen in
Ullrich CMD. Club feet are a feature of nemaline
myopathy and RYR1-related myopathies but are also
seen in congenital peripheral nerve hypomyelination
syndromes, CMS and DM1. Distal arthrogryposis
multiplex can be a feature of nemaline myopathy [21] and
can also be seen in a range of other neuromuscular
disorders (see Table 1) including CMS, and congenital
peripheral nerve hypomyelination. Severe arthrogryposis
in the setting of fetal akinesia sequence raises the
possibility of nemaline myopathy (most likely ACTA1-,
NEB-, or KLHL40-related) but has also been reported in
RYR1-related myopathies [16]. Important diﬀerential
diagnoses include CMS and rarely SMA type 0. The
King-Denborough syndrome is a peculiar manifestation of
certain RYR1 mutations associated with dysmorphic
features and often multiple orthopaedic abnormalities [22].4.2. Features in the older child
In the older child there may be additional clinical
features that can be suggestive of a speciﬁc subtype
within the congenital myopathies (Table 2). It is
important to point out that the congenital myopathies
are usually associated with generalised reduced muscle
bulk, although mild hypertrophy can be seen with some
dominantly inherited RYR1-related myopathies. In
general, muscle pseudohypertrophy should suggest an
alternative diagnosis such as a muscular dystrophy or
Pompe disease.
Scoliosis is possible in all of the congenital myopathies,
but may occur particularly early in the more severe
RYR1-related myopathies, nemaline myopathy, and
aﬀects most children by adolescence with SEPN1-related
myopathy [9]. Congenital muscular dystrophies due to
mutations in COL6, LAMA2 and LMNA are the major
diﬀerential diagnostic considerations. Patients with
SEPN1-related myopathy may present in infancy with
predominantly cervical weakness (dropped head
syndrome) and typically develop signiﬁcant spinal rigidity
prior to the development of scoliosis.
Foot drop and pes cavus is seen in the congenital
myopathies that include more distal muscle involvement,
such as those associated with NEB, TPM3, TPM2,
MYH7 and DNM2 mutations. The major diﬀerential
diagnosis is a peripheral neuropathic process so that
NCV/EMG studies should be performed to exclude
denervation.
Cardiomyopathy is not a typical feature in the congenital
myopathies, unless it occurs in the setting of cor pulmonale
due to respiratory insuﬃciency. If it occurs independent of
respiratory insuﬃciency, considerations should include
TTN- and MYH7-related myopathies. Very occasionally
it has been reported in ACTA1-related myopathy [23,24].
Episodes suggestive of malignant hyperthermia (MH)
such as development of a signiﬁcant fever peri-operatively
or in the immediate postoperative period, or
rhabdomyolysis associated with anaesthesia, strongly
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do signs of heat intolerance (such as excessive sweating
or a history of “heat stroke”) and exertional myalgia [25].
Respiratory involvement out of proportion to the skeletal
muscle weakness, such as nocturnal respiratory
insuﬃciency in an ambulant patient, is most typically
seen in SEPN1-related myopathy, but also in nemaline
myopathy related to NEB, TPM3 or ACTA1 mutations.
The most important diﬀerential diagnostic considerations
include juvenile Pompe disease, CMS (e.g., due to
CHAT, RPSN or ColQ mutations) in which the
respiratory failure may manifest suddenly, often
associated with intercurrent viral infection, and collagen
VI-related myopathy (see Table 2).5. Muscle biopsy
5.1. Speciﬁc structural pathological features that aid
diagnosis (Fig. 2, Tables 3 and 4)
5.1.1. Nemaline bodies (rods)
These are the characteristic features of nemaline
myopathies (Fig. 2). They stain red with the Gomori
trichrome technique. They vary in number per ﬁbre, per
muscle, and in distribution. They may be restricted to
type 1 ﬁbres, occur in peripheral clusters, in lines, or
scattered throughout ﬁbres. They may be diﬃcult to
identify if ﬁbres are very small and EM can then be
useful. There is no minimum number per biopsy for
diagnosis but they should be the most prominent
diagnostic histological abnormality in nemaline
myopathy. RYR1-related myopathies may show rods in
only a few ﬁbres. On EM, rods have a lattice structure
similar to the Z-line and can show continuity with theTable 3
Overlap between pathological features associated with speciﬁc gene defects.
Structural defect Genes 
Rods ACTA1,NEB,TPM2
KBTBD13, KLHL40
Cores RYR1, SEPN1, ACT
KBTBD13
Central nuclei MTM1, DNM2, BIN
Rods and cores RYR1, NEB, KBTBD
Caps TPM2, TPM3,  ACT
Congenital ﬁbre type disproporon ACTA1, TPM3, TPM
Distal myopathy no rods NEB
Distal arthrogryposis TPM2, MYH3, MYHZ-line. In some cases the rods may appear as thickened
Z-lines. Their shape can be rod-like or ovoid (depending
on orientation), and ﬁlaments may be attached to them.
Rods are usually cytoplasmic but occasionally are present
in the nucleus. Intranuclear rods are a feature of ACTA1
nemaline myopathy.
With immunohistochemistry, rods contain similar
proteins to Z lines, in particular, a-actinin. Haematoxylin
and eosin staining rarely identiﬁes the rods but in
patients with ACTA1 mutations, accumulation of actin is
observed as pale zones (and with trichrome staining),
which also show no ATPase or oxidative enzyme activity,
and are not immunolabelled with myosin antibodies. The
actin accumulation is observed on EM as accumulation
of ﬁlamentous material.
5.1.2. Cores
The appearance of cores can be variable. Classical
cores are distinct areas devoid of mitochondria and thus
also of oxidative enzyme activity, which may be rimmed
by a darker staining zone that may also be positive for
desmin. Cores may be peripheral or central, there may
be more than one per ﬁbre, and they extend down an
appreciable length of the ﬁbres. With ATPase,
structured cores are positive but unstructured cores
show an absence of ATPase activity. This distinction
does not aid diagnosis.
5.1.3. Minicores
Minicores are multiple focal areas devoid of oxidative
enzyme activity, but in transverse section they may only
appear as unevenness of stain. In longitudinal section
they appear as multiple focal areas [26]. Some large
multiple cores may stretch across the width of a ﬁbre
(some RYR1 cases, particularly if associated withDisease
,TPM3,TNNT1,CFL2,
 
Nemaline myopathies 
A1, TTN, MYH7, Core myopathies
1, RYR1,  (DM1)   Centronuclear myopathies
13, CFL2 Core-rod myopathy
A1 Cap disease
2, RYR1,SEPN1 
8, TNNTI2, TNNT3
Table 4
Pathological features that are associated with particular congenital myopathy genes.
Rods – nemaline rods; H & E – haematoxylin and eosin stain; EM – electron microscopy; FSD – ﬁbre size disproportion (consistent hypotrophy of type 1
ﬁbres compared to type 2 ﬁbres).
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areas of myoﬁbrillar disruption that aﬀect a variable
number of sarcomeres (minicores). Sometimes EM
reveals minimal disruption of myoﬁbrillar structure and
only areas of misaligned myoﬁbrils with sparse
mitochondria are seen (‘structured minicores’).
It is important to note that regions devoid of oxidative
staining that represent a lack of mitochondria can be due
to inclusions such as nemaline bodies or actin
accumulations that displace normal myoﬁbre organellesand structures, but these should not be regarded as true
cores. EM will help clarify these situations. Cores,
particularly minicores, are also a non-speciﬁc feature of
several disorders including muscular dystrophies (e.g.,
collagen VI and dystrophinopathies) and neuropathies.
They are also a non-speciﬁc ﬁnding adjacent to capillaries.
5.1.4. Central nuclei
Central nuclei inX-linkedmyotubularmyopathy (MTM)
are large and occupy a large volume of the ﬁbre. They are
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ﬁbres where they are often in continuous chains, although
this may occur in BIN1-related cases). Very few peripheral
nuclei are present in the X-linked form but are more
common in autosomal forms of CNM. The number of
central nuclei may increase with age, therefore it is not
possible to determine the minimum number for diagnosis
[27]. Central nuclei in neonates are often associated with
dark stained centres with a pale peripheral halo with
oxidative enzyme, which contain myoﬁbrils but sparse
mitochondria. This pathology is similar to that seen in
DM1 which must be excluded by genetic testing, and can
also be seen in some neonatal autosomal cases. Autosomal
forms of CNM (DNM2, BIN1, RYR1) show central nuclei
associated with more focal dark centres and, in DNM2
cases, strands radiating from the centre of the ﬁbre may be
seen with oxidative enzymes and/or PAS (radial
sarcoplasmic strands, see below). This feature may be less
apparent, or absent, in neonates or infants, and may be an
age-related feature [27].
Some patients withmutations inDNM2 andRYR1, often
in association with severe weakness, have prominent
endomysial ﬁbrosis and distinguishing these cases from
dystrophies on histopathological grounds alone can be
diﬃcult [15,16]. The presence of ptosis and
ophthalmoparesis on clinical examination is more
suggestive of CNM, whilst the presence of active ﬁbre
regeneration (positive staining with both developmental
and fetal myosin) and degeneration is more suggestive of a
muscular dystrophy.5.1.5. Caps
These are peripheral, well-demarcated areas that are
eosinophilic with H&E, and usually positive with
NADH-TR but sometimes negative [28]. They show no
ATPase activity and no myosin staining. They labelFig. 1. Facial involvement in congenital myopathies. (A) Pronounced facia
craniofacial dysmorphism (“myopathic facies”) in sisters aged 6 years and 3 mo
(B) Ptosis and ophthalmoplegia in a patient with DNM2-related centronucleapositively for actin and a-actinin. With EM, the caps are
focal, usually peripheral areas of haphazardly orientated
myoﬁlaments often with thickened Z-lines and thin
ﬁlaments attached [29].
5.1.6. Hyaline bodies
These focal areas are seen as granular, slightly
basophilic zones with H&E and negative for NADH-TR,
but positive for ATPase and slow myosin (opposite to
caps) [30]. With EM, they are seen as granular areas.5.1.7. Congenital ﬁbre type disproportion
The use of this term is best reserved for patients in
whom mean type 1 ﬁbre diameter is consistently at least
35–40% smaller than type 2 ﬁbres diameter in the absence
of other structural abnormalities, together with clinical
features of a congenital myopathy [31]. Mutations in
SEPN1, LMNA, and COL6 and myotonic dystrophy
(DM1) in particular may be associated with less marked,
and thus less speciﬁc, degrees of ﬁbre size disproportion
in the absence of other diagnostic histological features.
The best clues to these diagnoses come from clinical
examination. Small type 1 ﬁbres can occur in a wide
variety of muscle and non muscle disorders and are a
feature of most congenital myopathies [1]. CFTD is often
associated with type 1 ﬁbre predominance.
5.1.8. Necklace ﬁbres
These show a clear loop/ring of oxidative enzyme
staining, internal within the ﬁbre and not attached to the
sarcolemma. In MTM1-related CNM, this loop is
associated with internal nuclei. Necklace ﬁbres are a
particular feature of female MTM1 carriers, but may not
be speciﬁc for this genetic diagnosis [32]. Similar loops
but without associated nuclei have also been observed in
DNM2 cases [33].l weakness, particularly aﬀecting the lower face and mouth resulting in
nths with autosomal recessive nemaline myopathy (likely due to nebulin).
r myopathy at age 9 years.
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These are lines of NADH-TR and/or PAS staining
radiating from the centre of the ﬁbre which is often more
heavily stained. They are associated with DNM2-related
and BIN1-related CNM but they may be age-related as
they are less common in neonatal or childhood cases [15,34].Fig. 2. Pathological features that deﬁne the major subtypes of congenital my
with a dominant mutation in the ACTA1 gene, showing clusters of purple sta
(Gomori trichrome). (B) Central cores: Biopsy of the quadriceps from a three
ryanodine receptor gene showing mild variation in ﬁbre size (ﬁbre diameter ra
centrally or peripherally (oxidative enzyme stain SDH). (C) Central nuclei: Q
centronuclear myopathy due to a DNM2 mutation. The biopsy demonstrated
(H&E). (D) Central nuclei (longitudinal section): Quadriceps biopsy from a cas
nuclei. Note the widely spaced nuclei which aﬀects the number seen in transver
Areas in both ﬁbre types of varying size and number devoid of oxidative enzym
11 years with recessive mutations in the SEPN1 gene (NADH-TR). (F) Conge
pathology in this case was the small size of the dark-staining type 1 ﬁbres and ty
25–70 mm.5.1.10. Structures of possible or unknown genetic cause
A number of other rare structural features can occur in
muscle biopsies and be identiﬁed with various stains, and/
or EM, e.g., cytoplasmic bodies, concentric laminated
whorls, cylindrical spirals, tubular aggregates, ﬁngerprint
bodies, hexagonal crystalloid structures. The signiﬁcanceopathy. (A) Nemaline rods: Biopsy from patient with nemaline myopathy
ining rods at the periphery of most ﬁbres and some internal within ﬁbres
year old patient with central core disease with a dominant mutation in the
nge 15–65 mm), ﬁbre type uniformity and numerous cores of varying size
uadriceps biopsy from a 28 year old patient with autosomal dominant
small type 1 ﬁbres and centrally placed nuclei in the majority of ﬁbres
e of X-linked myotubular myopathy aged 8 months showing large central
se section Most ﬁbres are less than 10 mm in diameter. (E)Multiminicores:
e stain in a quadriceps biopsy from a case of ‘multi-minicore disease’ aged
nital ﬁbre type disproportion with mutation in ACTA1: The only apparent
pe 1 ﬁbre predominance (ATPase preincubated at pH 4.3). Fibre diameter
106 K.N. North et al. / Neuromuscular Disorders 24 (2014) 97–116of these and their possible genetic cause is not clear and
they are not considered in this article.5.2. Pathological features suggestive of a speciﬁc genetic
diagnosis
Some pathological features are common to most
congenital myopathies. These include pronounced type 1
predominance or uniformity, type 1 hypotrophy and very
small ﬁbres (less than 5 lm) that express fetal myosin,
although ﬁbres of larger size with fetal myosin may be
present in neonatal cases. In many congenital myopathies,
these features are associated with other pathological
features that can help to direct molecular analysis.
There is considerable overlap between the
pathological features associated with speciﬁc gene
defects. Mutations of the same gene can be associated
with a variety of pathological features and the same
morphological structure can be associated with several
defective genes (Table 3). Some pathological features
can help to direct molecular analysis in associationFig. 3. Muscle magnetic resonance imaging (MRI) in the diagnosis of the con
thigh (A–D) and the lower leg (E–H) in a normal control (A,E) and patients
related dominant centronuclear myopathy (CNM) (C,G) and NEB-related rec
(B,F), there is marked involvement of the thigh with relative sparing of rectus f
the lower leg, soleus (So), gastrocnemius lateralis (Gl) and peroneal group (PG)
and gastrocnemius medialis (Gm) are relatively spared. In DNM2-related dom
with prominent involvement of rectus femoris (RF) and adductor longus (A
involvement of all muscle groups with relative sparing of the tibialis posterior (T
spared whereas the lower leg shows early involvement of the tibialis anterior (A
early distal involvement in NM. (Composite image from [74,85,93]).with the clinical features (not all will be present in
each case) (Table 4).
6. Muscle MRI
Speciﬁc features on muscle MRI that aid diagnosis in
conjunction with clinical and pathological features are
demonstrated in Fig. 3 and summarised in the Table 5.
7. Genetic testing for congenital myopathies
Molecular testing for congenital myopathies is in rapid
evolution with recent advances in sequencing technology
likely to have considerable impact on the method of
genetic testing for these diseases. However, a challenge will
be to ensure that sequence changes identiﬁed are
pathogenic and to distinguish these from polymorphisms.
The Leiden Open Variation database is an excellent open
access resource that provides a list of DNA sequence
variants in speciﬁc genes and associated phenotypes to
assist in the identiﬁcation of which variants are pathogenic
(http://www.lovd.nl/).genital myopathies: T1-weighted images, transverse sections, through the
with RYR1-related dominant central core disease (CCD) (B,F), DNM2-
essive nemaline myopathy (NM) (D,H). In RYR1-related dominant CCD
emoris (RF), adductor longus (AL), gracilis (G) and hamstring muscles. In
are markedly aﬀected whereas tibialis anterior (AT), tibialis posterior (TP)
inant centronuclear myopathy (CNM) (C,G), the thigh is diﬀusely aﬀected
L) compared to other muscle groups. In the lower leg, there is diﬀuse
P). In NEB-related recessive nemaline myopathy (NM) (D,H), the thigh is
T) and, to a lesser extent, soleus (So), in keeping with the clinical ﬁnding of
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myopathies has usually not been practical for multiple
reasons. As discussed above, the clinical features of
individual congenital myopathies overlap considerably
and it is rarely possible to predict the genetic cause on
clinical examination alone, although increased use of
muscle MRI may make this possible in some situations.
Nevertheless, going straight to speciﬁc genetic testing has
been used in the following circumstances:
 To exclude an alternative diagnosis: for example severe
spinal muscular atrophy (SMA Type 0) or congenital
myotonic dystrophy (DM1).
 Where the muscle biopsy may not be helpful but the
clinical phenotype may be characteristic, such as the
selenoprotein 1 – (SEPN1) and the lamin A/C –
(LMNA/C) related myopathies.
 In the rare case where there is a severely ill neonate in
whom a congenital myopathy is a possibility and the
decision to withdraw care is being considered. Genetic
testing for X-linked centronuclear/myotubular
myopathy, (MTM1), congenital myotonic dystrophy
(DM1), congenital severe nemaline myopathy (ACTA1
and KLHL40) may be appropriate if a biopsy cannot
be obtained ante-mortem. It is important in these
circumstances to collect muscle biopsy (more than one
muscle e.g., quadriceps and deltoid), blood for DNA
and to establish a ﬁbroblast cell line immediately after
death.
In general, genetic testing should be prioritised based on
a combination of information gained from clinical
presentation and examination, family history, muscle
biopsy ± muscle MRI.
7.1. Genetic diagnosis of individual congenital myopathies
(Table 5)
For availability of genetic tests in diﬀerent countries – in
both diagnostic and research laboratories we recommend
Genetests (www.genetests.org) as an up-to-date internet
resource.
7.1.1. Nemaline myopathy
To date, eight genes have been identiﬁed for nemaline
myopathy: a-skeletal actin, (ACTA1); muscle-speciﬁc
coﬁlin (CFL2); nebulin (NEB); slow troponin T
(TNNT1); b-tropomyosin (TPM2), slow a-tropomyosin
(TPM3), and kelch-like family member 40 (KLHL40);
muscle-speciﬁc ubiquitin ligase (KBTBD13) can cause
both core-rod myopathy and nemaline myopathy (see
below).
It is likely that 40–50% of nemaline myopathy cases
are due to nebulin (NEB) mutations, although the exact
proportion has yet to be conclusively proven. All patients
with NEB mutations to date have autosomal recessive
disease. The NEB gene is a large gene and there are nocommon mutations or mutation hotspots, except for a
founder mutation in the Ashkenazi Jewish population [35].
a-Skeletal actin (ACTA1) mutations cause 20–25% of all
nemaline myopathy, but 50% of severe nemaline
myopathy. The a-skeletal actin (ACTA1) gene is small
and relatively easy to analyse. Most mutations (90%)
are dominant missense changes. For the majority of
patients, parental testing will show de novo occurrence in
the child (i.e., neither parent carries the mutation in their
germline DNA isolated from blood), but there can rarely
be somatic, including germline, mosaicism, in one parent
[2]. Autosomal dominant inheritance of mild disease can
occur. Approximately 10% of patients with ACTA1
mutations have recessive mutations, with a higher
incidence of recessive mutations in certain populations
[1]. All known recessive mutations tested are genetic or
functional null alleles. The recessive a-skeletal actin
(ACTA1) patients retain expression of cardiac actin, the
fetal isoform of actin in skeletal muscle, in all muscle
ﬁbres. It is important to note that no missense
polymorphisms have been reported to date in ACTA1.
Slow a-tropomyosin (TPM3) analysis should
particularly be considered if nemaline rods are restricted
to type 1 (slow) muscle ﬁbres. TPM3 gene mutations
may result in autosomal dominant or recessive disease,
although de novo dominant and autosomal dominant
inheritance is more common in the cases described to
date [36]. b-Tropomyosin (TPM2) analysis should be
especially considered for mild dominant disease [36].
Slow troponin T (TNNT1) mutations have only been
described to date in the old order Amish population [37].
However it is possible that TNNT1 mutations may,
rarely, occur in other populations.
Mutation of muscle-speciﬁc coﬁlin (CFL2) is a rare
cause of nemaline myopathy, having been described in
two families to date [38,39].
Mutations in KLHL40 (kelch-like family member 40,
also known as KBTBD5) have been identiﬁed as a
frequent cause of severe autosomal recessive NEM (28/
143 congenital severe NEM kindreds) [40]. Patients
presented with fetal akinesia/hypokinesia and
contractures, fractures, respiratory failure and swallowing
diﬃculties at birth, with death frequently in utero or in
the newborn period. In the Japanese, KLHL40 mutations
are the most common cause for this severe form of
NEM, accounting for up to 28% of the tested individuals.
7.1.2. Central core disease (CCD)
Where histological changes and clinical features are
typical of CCD, most patients (at least 2/3 of patients
[41] and more than 90% in one described series [42]) have
dominant changes in the ryanodine receptor gene
(RYR1). Around 60% of RYR1 CCD mutations are in
the CCD hotspots including the C-terminal region. For
presumed dominant mutations, parental studies should be
performed. If one parent has the change and is
asymptomatic, there is a high suspicion of recessive
Table 5
Clinical and MRI clues to genetic diagnosis (See below-mentioned references for further information).
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to identify a second mutation. It must be noted that
dominant RYR1 mutations can be associated with
variable expressivity, and some aﬀected family members
may have only very mild weakness. Sequencing of all
exons and ﬂanking regions may be required to identify all
pathogenic changes in the coding region. Rarely deep
intronic changes that aﬀect splicing or large deletions
may only be apparent on sequencing cDNA generated
from frozen muscle or using speciﬁc protocols for
deletion detection [43,44]. Analysis of cDNA may clarify
the presence of null alleles, although this technique is not
widely available in diagnostic centres.
Variants of uncertain signiﬁcance are an important
problem in the RYR1 gene. Use of locus-speciﬁc
databases for each gene, including depositing variant
information from all labs analysing each gene into the
locus-speciﬁc databases, also greatly helps clarify the
signiﬁcance of any variant identiﬁed.
Mutations in ACTA1 may be associated with core-like
areas [45].
7.1.3. Multi-minicore disease
If there is a typical clinical phenotype for selenoprotein
1 (SEPN1) disease, this should be sequenced ﬁrst. All
patients to date have had autosomal recessive disease [9].
Rare mutations are outside the coding region, but aﬀect
the SECIS element in the 30 UTR [46].
The ryanodine receptor gene (RYR1) should be
considered as the second most likely gene. Many
recessive RYR1 patients will have ophthalmoplegia
(which is not a reported feature in the SEPN1-related
form), ptosis and prominent facial weakness, as well as
increased central and internal nuclei. Recessive mutations
predominate [26,43]. Monoallelic expression, due to
genetic mechanisms that are currently unclear, has also
been reported [47].
If there is associated cardiomyopathy, MYH7 [48] and
titin (TTN) analysis should be considered [23].
It is important to note that minicores can be a feature of
several congenital myopathies and many other disorders,
such as muscular dystrophies, and myopathies associated
with collagen VI.
7.1.4. Core-rod diseases
Core-rod disease is characterised by the presence of
both central cores and nemaline bodies upon muscle
biopsy, including in the same or separate muscle ﬁbres,
although areas with rods will appear as cores as they
lack mitochondria. The most common cause of true
core-rod myopathy is the RYR1 gene, and both
dominant and recessive mutations have been described
[49–51].
Nebulin mutations are an uncommon cause of recessive
core-rod disease [52,53].
Another locus for core-rod disease was described on
chromosome 15 [54] and mutations in a muscle-speciﬁcubiquitin ligase, KBTBD13 have recently been identiﬁed
[90]. Some of these individuals had rods as the
predominant pathology and could be classiﬁed as
nemaline myopathy. Clinically this should be suspected in
patients with “slowness” of muscle movements in
addition to proximal weakness.
7.1.5. Centronuclear myopathies
In severely aﬀected males, the myotubularin gene
(MTM1) should be tested ﬁrst. Rare mutations are
intronic and are not identiﬁed on sequencing of the
coding exons and ﬂanking regions. Complex genomic
rearrangements associated with XLMTM have also
been reported recently [55,56]. Analysis of cDNA
generated from muscle biopsy is recommended for
patients with the typical phenotype to fully exclude
MTM1 if a mutation is not identiﬁed on genomic
DNA [57].
If there is a clear autosomal dominant family history,
and consistent clinical features (with or without muscle
MRI) dynamin 2 (DNM2) should be sequenced ﬁrst [58].
De novo mutations are relatively common, particularly in
patients with severe phenotypes [15]. Parental studies are
recommended to check that the gene change segregates
with the disease. Non-penetrance has not been described
to date.
Ryanodine receptor (RYR1) mutations usually cause
autosomal recessive CNM [18]. Caution must be
exercised to exclude autosomal recessive inheritance if
only a single mutation is found, as described above for
central core disease.
Males and females with CNM and mild or moderate
muscle weakness can uncommonly have mutations in the
myotubularin (MTM1) gene. In females, manifesting
carriers may have skewed X-inactivation and may be
severe. A pathological clue in these patients may be the
presence of necklace ﬁbres [32].
Amphiphysin 2 (BIN1) mutation is a cause of
autosomal recessive centronuclear myopathy in only a
few reported cases and appears to be a rare cause of the
disease [59,60].
7.1.6. Congenital ﬁbre type disproportion (CFTD)
Slow a-tropomyosin (TPM3) is the most common
known genetic cause of CFTD, accounting for 25–40% of
patients and usually follows autosomal dominant
inheritance [10,61]. Many mutations are de novo
dominant mutations. All patients to date have had mild
disease, and remain ambulant as adults.
Ryanodine receptor (RYR1) mutations have been found
in around 20% of patients and may be associated with
marked ﬁbre size disproportion (>50%) [62]. All patients
to date have had autosomal recessive disease.
a-Skeletal actin (ACTA1) is an uncommon cause
(around 5%) of patients and may be associated with
severe muscle weakness. All patients to date have had de
novo dominant mutations [5].
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CFTD [63].
One family has been reported with an X-linked form but
the genetic cause has not been identiﬁed [64].
7.1.7. Hyaline body myopathy(/myosin storage myopathy)
All patients with classical histological features have had
mutations in the C-terminal region of slow skeletal
b-cardiac myosin (MYH7) (exons 35–40). Most patients
to date have had autosomal dominant (including de novo)
mutations but one recessive mutation has been described
[30,65,66].
7.1.8. Cap disease
Cap disease is considered to be a variant of nemaline
myopathy and to date is most often due to dominant
mutations in b-tropomyosin (TPM2) [67,68] and slow
a-tropomyosin (TPM3) [69,70]. A mutation in a-
skeletal actin (ACTA1) has been identiﬁed in one case
to date [6].
7.1.9. Zebra body myopathy
Zebra body myopathy is also considered to be a variant
of nemaline myopathy and a mutation in ACTA1 has been
identiﬁed in one of the only 2 cases reported to date [7].
7.2. Interpreting genetic testing
Genetic testing for many congenital myopathies is
relatively new. Therefore, many tests may result in variants
of uncertain signiﬁcance. This is particularly common for
the RYR1 gene as noted above, and for other large muscle
genes such as NEB that have a large number of variants
proportional to their large size. Family studies can be very
helpful to clarify the situation. In dominant disorders, if a
sequence change is present in other healthy family members,
then it is unlikely to be disease-causing, or is dominant with
reduced penetrance. Similarly, if a healthy sibling has
inherited the same pattern of alleles at a recessive genetic
locus then this disorder is essentially excluded in the family.
If clinicians have any questions about the interpretation of
genetic results or the inheritance pattern, or if the results are
incongruous with the disease presentation or family history,
they should seek advice from the laboratory or a specialist
neuromuscular service.
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